Dr. Komanduri on Emerging Therapies for Patients With Hematologic Malignancies

Krishna Komanduri, MD
Published Online: Friday, Jan 08, 2016



Krishna Komanduri, MD, professor of Medicine, Microbiology, and Immunology, director, Sylvester Adult Stem Cell Transplant Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses future treatments for patients with hematologic malignancies.

Oncologists have been working to gain a deeper understanding of the power of the immune system, how it is regulated, and how it positively and negatively affects outcomes of patients with cancer. This is a golden era of immunotherapy, Komanduri explains.

In hematologic malignancies, Komanduri says multiple FDA approvals of checkpoint inhibitors can be expected. The approval of chimeric-antigen receptor T-cell therapy will likely occur in 2017, he predicts. Allogeneic stem cell transplantation will also continue to evolve the treatment paradigm.



Krishna Komanduri, MD, professor of Medicine, Microbiology, and Immunology, director, Sylvester Adult Stem Cell Transplant Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses future treatments for patients with hematologic malignancies.

Oncologists have been working to gain a deeper understanding of the power of the immune system, how it is regulated, and how it positively and negatively affects outcomes of patients with cancer. This is a golden era of immunotherapy, Komanduri explains.

In hematologic malignancies, Komanduri says multiple FDA approvals of checkpoint inhibitors can be expected. The approval of chimeric-antigen receptor T-cell therapy will likely occur in 2017, he predicts. Allogeneic stem cell transplantation will also continue to evolve the treatment paradigm.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
OncoLogue Case Discussions™: Smoldering Myeloma: To Treat or Not to Treat?Jun 22, 20171.5
Advances in™ Targeted Therapies: The Emerging Role of PI3K Inhibitors in the Treatment of Hematologic MalignanciesNov 16, 20171.5
Publication Bottom Border
Border Publication